| Sally York, MD PHD | |
|
3601 The Vanderbilt Clinic, Nashville, TN 37232-0021 | |
| (615) 936-2000 | |
| Not Available |
| Full Name | Sally York |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 28 Years |
| Location | 3601 The Vanderbilt Clinic, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942384821 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 97-01669 (North Carolina) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD49013 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vanderbilt University Medical Center | 5092023416 | 2711 |
News Archive
Mothers that take excessive amounts of folic acid during pregnancy may predispose their daughters to diabetes and obesity later in life, according to a new study published today in the Journal of Endocrinology. With high dose supplements being widely available, the study calls for a need to establish a safe upper limit of folic acid intake for pregnant women.
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
Medicare's new payment method for reimbursing physicians for prescription drugs under Part B has reduced spending, according to a report to Congress prepared by the Medicare Payment Advisory Commission, CQ HealthBeat reports.
Amedica Corporation, a developer of a broad range of innovative, unique spine and total joint implants, announced that it has completed a $30 million financing. The financing consists of $15 million in private equity and a debt facility of $15 million. Zions First National Bank provided the debt facility, and Creation Capital of New York and Austin, Texas, acted as the placement agent for the private equity piece. Creation Capital is an established banking concern that specializes in high-growth emerging health care technologies.
› Verified 1 days ago
| Entity Name | Vanderbilt University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104202761 PECOS PAC ID: 5092023416 Enrollment ID: O20151006000369 |
News Archive
Mothers that take excessive amounts of folic acid during pregnancy may predispose their daughters to diabetes and obesity later in life, according to a new study published today in the Journal of Endocrinology. With high dose supplements being widely available, the study calls for a need to establish a safe upper limit of folic acid intake for pregnant women.
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
Medicare's new payment method for reimbursing physicians for prescription drugs under Part B has reduced spending, according to a report to Congress prepared by the Medicare Payment Advisory Commission, CQ HealthBeat reports.
Amedica Corporation, a developer of a broad range of innovative, unique spine and total joint implants, announced that it has completed a $30 million financing. The financing consists of $15 million in private equity and a debt facility of $15 million. Zions First National Bank provided the debt facility, and Creation Capital of New York and Austin, Texas, acted as the placement agent for the private equity piece. Creation Capital is an established banking concern that specializes in high-growth emerging health care technologies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sally York, MD PHD 3841 Green Hills Village Dr Ste 200, Nashville, TN 37215-2691 Ph: () - | Sally York, MD PHD 3601 The Vanderbilt Clinic, Nashville, TN 37232-0021 Ph: (615) 936-2000 |
News Archive
Mothers that take excessive amounts of folic acid during pregnancy may predispose their daughters to diabetes and obesity later in life, according to a new study published today in the Journal of Endocrinology. With high dose supplements being widely available, the study calls for a need to establish a safe upper limit of folic acid intake for pregnant women.
IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) ("IntelGenx") previously announced that the New Drug Application (NDA) filing for the antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma") had been accepted by the U.S. Food and Drug Administration (FDA) for standard review. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL®.
Medicare's new payment method for reimbursing physicians for prescription drugs under Part B has reduced spending, according to a report to Congress prepared by the Medicare Payment Advisory Commission, CQ HealthBeat reports.
Amedica Corporation, a developer of a broad range of innovative, unique spine and total joint implants, announced that it has completed a $30 million financing. The financing consists of $15 million in private equity and a debt facility of $15 million. Zions First National Bank provided the debt facility, and Creation Capital of New York and Austin, Texas, acted as the placement agent for the private equity piece. Creation Capital is an established banking concern that specializes in high-growth emerging health care technologies.
› Verified 1 days ago
Megan Desai, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4220 Harding Pike, Nashville, TN 37205 Phone: 615-222-6726 Fax: 615-222-3702 | |
Harrison Klause, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
John N Bowers, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike Ste 500, Nashville, TN 37205 Phone: 629-255-2493 Fax: 629-255-4266 | |
Dr. Evan Zehr, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1161 21st Ave S, Nashville, TN 37232 Phone: 615-322-6943 | |
Spurthi N Bhatt, MD MPH Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Mr. Robert M Johnson, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2410 Patterson St, Suite 106, Nashville, TN 37203 Phone: 615-340-4611 Fax: 615-340-4658 | |
Mr. John E Anderson, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St, Suite 400, Nashville, TN 37203 Phone: 615-342-5900 Fax: 615-342-5912 |